A selective PDE4D inhibitor, BPN14770, has shown promise in treating Fragile X syndrome by reducing hyperarousal and improving social interactions. The treatment also exhibited long-term benefits, with no tolerance observed.
Researchers have found that Aravive-S6 can inhibit Zika infection of human glial cells, adding to its previously reported anticancer properties. The study suggests a potential antiviral role for the molecule in treating neurological disorders caused by the virus.
A new study reveals that inhibiting AXL signaling increases anti-tumor immune response, sensitizes tumors to radiation, and enhances efficacy of anticancer therapies. Aravive-S6 acts as a decoy receptor, binding Gas-6 to prevent AXL activation.
A broadly neutralizing cross-reactive antibody targets multiple virulence factors of Staphylococcus aureus, including alpha-hemolysin. The antibody shows high protective efficacy in animal models and is being developed as Arsanis' ASN100 product candidate.
A new theory proposes that stimulating mitochondrial function and superoxide production can improve markers of renal, cardiovascular, and nerve dysfunction in diabetes. This approach may help promote tissue healing and is linked to improved outcomes for diabetic kidney disease.
The study demonstrates BioMAP Systems' effectiveness in identifying potential toxicities and off-target effects of drugs and chemicals. The approach can reproducibly pinpoint cellular mechanisms and biomarker endpoints underlying specific adverse reactions in humans.
A large prospective study of 1000 patients found significantly reduced major CIED infections with TYRX AIGISRx Antibacterial Envelope, down to 95% fewer than control cohorts. The study also showed no unanticipated serious AIGISRx-related adverse events.
A clinical study demonstrates the effectiveness of an automated insulin dosage titration system in improving blood glucose control and reducing hypoglycemic events. The system, developed by Hygieia, Inc., automatically updates insulin dosage for patients with type 2 or type 1 diabetes, leading to improved glycemic targets.
A highly targeted bactericidal protein against the life-threatening foodborne E. coli O104 strain was rapidly created, demonstrating its ability to specifically bind and kill tested E. coli strains that produce the O104 lipopolysaccharide antigen.
A novel antibacterial protein, Avidocin, demonstrates potential for preventing and treating E. coli O157:H7-induced diarrhea and intestinal inflammation in an animal study. The protein also carries fewer bacteria in the feces of infected animals, making it a promising alternative to conventional antibiotics.
New Zealand's strategic approach to health care, from patient to provider and community, has enabled the development of integrated care services. The country's experience with electronic medical records and health IT systems has helped make it a leader in overall quality of care delivery.
NextBio's web-based tools aid in assessing potential drug efficacy and adverse effects by analyzing publicly available genomic data, identifying correlations with gene expression changes and cancer profiles.
A new study of over 200,000 Medicare beneficiaries found that cardiac device infections result in extremely high costs and patient mortality rates, even after hospital discharge. The study highlights the need for infection prevention as a key component of reducing mortality and morbidity.
Cardiac device infections lead to significant increases in hospital stay, hospitalization costs, and mortality rates, including up to double the mortality after one year. The study found that more than one-third of excess mortality occurred after hospital discharge.
A large COMMAND clinical study found a 99.5% successful implantation rate and 0.48% overall infection rate for patients using TYRX's AIGISRx Antibacterial Envelope. The envelope reduces infections in high-risk patients by 70% compared to previous studies.
A non-absorbed oral co-polymer therapy under development by Midway Pharmaceuticals demonstrates ability to protect against radiation damage and prevent lethal bacterial infections in animal models. The compound, PEG 15-20, may provide new way to prevent serious GI side effects of radiation in cancer patients.
LX211 controls inflammation in non-infectious uveitis, significantly reducing its recurrence rate by 50% at a dose of 0.4 mg/kg twice daily. The treatment also preserves visual acuity and reduces corticosteroid use to minimize vision loss risk.
ChemGenex's omacetaxine shows durable hematological and cytogenetic responses in patients with highly resistant CML. The Phase 2/3 study demonstrated a complete hematologic response rate of 85% in chronic phase patients, suggesting a promising treatment option for this difficult-to-treat population.
The LUMINATE trials demonstrate the ability of LX211 to significantly improve chronic eye inflammation in patients with uveitis. The study results also show a safety profile for LX211, allowing it to be suitable for chronic use as the first oral treatment for this sight-threatening inflammatory eye disease.
Innate Therapeutics' novel microparticle-based immune response modifier MIS416 significantly inhibited tumor growth and metastasis in lung and breast cancers. Administered as an adjunct to localized tumor irradiation, MIS416 demonstrated synergistic activity against recurrent lung tumors.
Researchers found omacetaxine killed 90% of leukemic stem cells in vitro and prolonged survival in test animals with resistant CML. The findings may open the door to developing a curative treatment strategy for some patients with CML.
The integration of sophisticated medical technologies with advanced information systems and clinical expertise can significantly improve patient care while lowering treatment costs. Real-time monitoring technologies, such as Zephyr's Smart Fabric technology, can detect key metabolic functions and provide significant savings in chronic ...
A panel of industry representatives emphasizes the importance of biotechnology in creating sustainable industries. Key findings include the potential for biomaterials and sustainable industrial processes to reduce reliance on petrochemicals and promote environmentally sound agricultural methods.
Nucleonics has initiated a Phase 1 human safety study of its experimental treatment NUC B1000, an expressed interfering RNA-based product designed to target and destroy HBV within infected cells. The therapy aims to reduce viral antigen load and potentially resolve viral infection in patients with mild to moderate disease.
A Phase 1 study using an adeno-associated virus vector to deliver an inhibitory gene to the subthalamic nucleus demonstrated a lack of adverse events and statistically significant improvements in clinical symptoms and brain metabolism. The treated side showed notable improvement, with sustained benefits observed over 12 months.
ChemGenex's lead compound Ceflatonin demonstrates clinical activity against Gleevec-resistant CML patients with the T315I Bcr-Abl mutation. A significant reduction in T315I levels and complete disappearance of the mutation were observed, indicating a potential therapeutic alternative for these patients.
The study demonstrated that genotyping can optimize Quinamed dosing for improved tolerance and antitumor activity. Patients with slow acetylator genotypes showed evidence of anticancer activity in various tumor types, including prostate, ovarian, and gastrointestinal stromal tumors.
LCT reports a major breakthrough in islet transplantation, with a human patient showing evidence of live porcine islet cells and insulin production ten years after the transplant. The study demonstrates the long-term safety and viability of LCT's encapsulated porcine islets without immunosuppression.
GlycoFi and Dartmouth researchers engineered yeast cells to produce a broad repertoire of recombinant therapeutic proteins with human sugar structures. This achievement eliminates the need for mammalian cell culture, improving control over glycosylation and performance characteristics of therapeutic proteins.
Researchers at HortResearch have fine-tuned gene discovery to accurately determine fruit flavors and fragrances, enabling the creation of 'Nature Identical' compounds. Biofermentation techniques can produce desired compounds at low cost and environmental impact.
Researchers at Origen successfully culture primordial germ cells from chicken embryos, introducing genetic elements into the chicken genome. This breakthrough enables efficient and cost-effective production of human protein therapeutics in eggs, with potential applications for treating cancer and other diseases.
Researchers at HortResearch have completed public release of world's most extensive apple DNA sequences, unlocking secrets of taste, health and color. The release comprises over 50,000 apple gene sequences, enabling fruit breeders to create new varieties tailored to consumer tastes and industry demand.
Researchers at GlycoFi have successfully produced human-glycosylated antibodies in yeast, improving cell killing and drug characteristics. This breakthrough allows for unprecedented control and uniformity of glycosylation, enabling optimization of therapeutic proteins.
Researchers have successfully produced human monoclonal antibodies in chicken eggs, demonstrating enhanced cell killing activity compared to conventionally produced antibodies. The new technology has the potential to drive down drug manufacturing costs and make medicines more affordable.
The Targacept compounds demonstrate a long-lasting effect on cognition by normalizing acetylcholine levels, a key neurotransmitter for cognitive processing. This mechanism of action suggests potential treatment for CNS disorders such as dementia, depression, and pain.
Scientists at LUCA Technologies have confirmed the presence of living methanogenic organisms in coalfields, producing methane in real-time. This finding suggests a potential long-term source of renewable natural gas, replacing finite energy resources.
A study published in Diabetes shows that six months treatment with Laszarin TM reduces heart size in diabetic patients and reverses heart failure. The research led by Protemix demonstrates that defective copper metabolism is implicated in the development of heart disease.
The Guava EasyCD4 and EasyCD8 assays provide comparable accuracy to flow cytometry methods but are simpler and more affordable, enabling global access to affordable HIV/AIDS patient monitoring. These lower-cost alternatives can significantly improve quality of care and life for millions of HIV+ patients in resource-limited countries.
Researchers identified 31 novel polypeptide families that inhibit Staphylococcus aureus growth when expressed in bacteria. They used phage genomics to screen for small molecule inhibitors and found several compounds that inhibited bacterial growth and DNA synthesis.
A Phase II clinical study of TP10 found that the complement inhibitor significantly reduced heart attacks and death in male patients undergoing open heart surgery. The study showed a significant decrease in composite endpoints for death, myocardial infarction, and prolonged intubation in males treated with TP10.
Researchers have discovered a novel molecular mechanism that explains why certain Hsp90 inhibitors are effective against tumor cells while being non-toxic to normal tissues. This breakthrough has significant implications for the development of targeted cancer therapies and may lead to new treatments for various types of cancer.
Studies presented at ICAAC reveal significant clinical outcomes, resource utilization, and infection-associated costs of Staph aureus bacteremia among hemodialysis-dependent patients. The infections are associated with substantial morbidity and mortality, underscoring the need for a vaccine to prevent these infections.
Researchers at PhageTech identified phage-derived antimicrobial proteins that inhibit bacterial growth and kill bacteria in diverse ways. The company's technology platform has led to the discovery of novel bacterial targets essential to bacterial growth, which are being screened for small molecule compounds as potential new antibiotics.
A team of scientists at GlycoFi, Inc. and Dartmouth College reports the successful production of a human protein with complex glycosylation in genetically modified yeast. The achievement enables the generation of glycoprotein libraries for elucidating specific structure-function relationships and identifying efficacious molecules.
AVANT Immunotherapeutics awarded subcontract to develop oral combination vaccine against anthrax and plague using proprietary technologies. The vaccine aims to offer rapid, effective protection from multiple biological agents with a single dose, eliminating the need for protracted dosing regimens.
CP461 acts against cancer cells selectively through both apoptosis and anti-angiogenic effects, preventing new blood vessel formation. The compound also disrupts microtubule organization and proper spindle formation, blocking mitosis and promoting cell death in cancer cells.
ChemGenex researchers used chemical genomics to identify molecular targets for Quinamed(TM) and predict anti-angiogenic properties for Ceflatonin(TM). These methods allowed the company to streamline drug discovery and validation, as well as identify potential side effects.
The Nabi experimental vaccine reduced bloodstream infections caused by Staphylococcus aureus in end-stage kidney disease patients by nearly 60%. The vaccine elicited a significant antibody response in 86% of the patients, and significantly reduced the incidence of systemic S. aureus infection in the blood.
ChemGenex Therapeutics has developed a new anticancer drug called Ceflatonin, which uses genomics to predict possible side effects and identify key genes for treatment. The company's research demonstrates that Ceflatonin affects specific genes and cellular pathways in leukemia and solid tumors.
Preclinical studies demonstrated PT-141's ability to increase precopulatory sexual behaviors in female rodents. The peptide analog stimulated melanocortin receptors, which play a role in appetite and sexual arousal. Palatin expects PT-141 to offer a unique treatment for women with desire disorders.